

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Otsuka Pharmaceutical Co. Ltd.	06/14/2013
RECEIVING PARTY DATA	
Name:	MethylGene Inc.
Street Address:	7150 Frederick-Banting
City:	Montreal, Quebec
State/Country:	CANADA
Postal Code:	H4S 2A1
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12964289
CORRESPONDENCE DATA	
Fax Number:	3128762020
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(312)876-1800
Email:	adiaz@woodphillips.com
Correspondent Name:	Wood, Phillips, Katz, Clark & Mortimer
Address Line 1:	500 West Madison Street
Address Line 2:	Suite 1130
Address Line 4:	Chicago, ILLINOIS 60661
ATTORNEY DOCKET NUMBER:	MET10638P00042US
NAME OF SUBMITTER:	Mark Polyakov
Signature:	/Mark Polyakov/
Date:	08/01/2013
Total Attachments: 1 source=MET42Assignment#page1.tif	

CH \$40.00 12964289

ASSIGNMENT

WHEREAS, Otsuka Pharmaceutical Co. Ltd., a corporation organized and existing under the laws of Japan, having a place of business at 2-9 Kanda-Tsukasamachi, Chiyoda-ku Tokyo, 101-8535, Japan, hereinafter called the "Assignor," having 50% of the entire right, title and interest in the invention described in the United States Patent Application entitled "Inhibitors of Protein Tyrosine Kinase Activity" that has a U.S. Patent Application Serial Number 12/964,289 and was filed on December 9, 2010;

WHEREAS, MethylGene Inc., a corporation organized and existing under the laws of Canada, having a place of business at 7150 Frederick-Banting, Montreal, Quebec, H4S 2A1, Canada, hereinafter called the "Assignee", desires to acquire all of Assignor's rights, title and interest in and to the invention and the patent application identified above, and all patents which may be obtained for said invention, as set forth below.

NOW THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignor has sold, assigned and transferred, and by these presents does sell, assign and transfer to the Assignee, all of its rights, title and interest in the United States in and to the invention and the patent application identified above, and any patents that may issue for said invention in the United States; together with the full right to claim for any such application all benefits and priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, re-issues, renewals and extensions of any of the patent applications or patents; to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.


The Assignor hereby covenants and agrees that Assignor has the full right to convey the interest assigned by this Assignment; and that the Assignor will assist the Assignee in the prosecution of the patent applications identified above, and in assisting Assignee in enforcement of any rights arising out of the Assignment; and that the Assignor will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Agreement.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, THE Assignor has executed this agreement.

DATED: June 14, 2013

Otsuka Pharmaceutical Co. Ltd.

By: 
Name: Seiji EJIMA
Title: Director of Intellectual Property Department